CDMRP: FY26 Lung Cancer Research Program (LCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Act now to prepare for the FY26 Lung Cancer Research Program (LCRP) funding opportunities — anticipated to open on Grants.gov imminently. This chance is critical for investigators aiming to drive innovative, high-impact research that will eradicate deaths and suffering from lung cancer, with a focus on outcomes that benefit Service Members, Veterans, their families, and the general public. Exact pre-application and application deadlines will be posted in the final NOFOs on Grants.gov when released.

How much funding would I receive?

Award amounts for the FY26 LCRP are specified by mechanism:

• Idea Development Award: Up to $800,000 total costs over 3 years.

• Translational Research Award (Level 1): Up to $1.35M total costs over 3 years.

• Translational Research Award (Level 2 – Clinical Trial Option): Up to $1.85M total costs over 4 years.

• Patient-Centered Outcomes and Survivorship Award: Up to $975,000 total costs over 3 years.

What could I use the funding for?

Funding supports research in the following Areas of Emphasis:

• Biology & Etiology: Mechanisms of lung cancer initiation and progression.

• Prevention & Risk Reduction: Innovative prevention and recurrence reduction strategies.

• Detection, Diagnosis & Surveillance: Improved early detection and disease monitoring.

• Treatment & Prognosis: Novel treatments, biomarkers, and metastasis management.

• Health Outcomes & Survivorship: Survivorship quality of life, comorbidity impacts, and disparities reduction.

Each mechanism has specific focus and eligibility criteria detailed in the forthcoming NOFOs.

Are there any additional benefits I would receive?

The pre-announcement does not specify additional benefits (e.g., data resources or training support). These may be described in the final funding opportunity announcements.

What is the timeline to apply and when would I receive funding?

• Pre-application and application deadlines: Not yet released; will be included in the NOFOs on Grants.gov once published.

• Funding decisions: Award timing will follow the CDMRP review process described in the final announcements.

Where does this funding come from?

Funding arises from the FY26 Defense Appropriations Act and is administered through the Congressionally Directed Medical Research Programs (CDMRP) within the Defense Health Agency Research and Development.

Who is eligible to apply?

Eligibility (e.g., investigator types, institution requirements) will be outlined in the final NOFOs. The pre-announcement does not include full eligibility details.

What companies and projects are likely to win?

Applicants are more competitive if they:

• Align tightly with one or more Areas of Emphasis.

• Demonstrate innovation and potential clinical impact.

• Address relevance to military health (e.g., Veteran populations, exposures).

Are there any restrictions I should know about?

• Some mechanisms (e.g., Idea Development) do not allow clinical trials.

• Specific restrictions and requirements will be in the NOFOs once released.

How long will it take me to prepare an application?

Preparation time depends on the mechanism, project maturity, and whether preliminary data or partnerships are needed. Start planning now to align with the mechanisms and Areas of Emphasis.

How can BW&CO help?

BW&CO can help you:

• Decode the final NOFO requirements.

• Align your research strategy to maximize impact.

• Draft and polish pre-applications/ applications.

• Manage submission logistics and compliance.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Peer Reviewed Cancer Research Program (PRCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Peer Reviewed Cancer Research Program (PRCRP) Pre-Announcement invites investigators to prepare for upcoming funding opportunities for innovative, high-impact cancer research that supports military health and mission readiness. Final Funding Opportunity Announcements (FOAs) with deadlines will be posted on Grants.gov; investigators should begin planning now. The deadline for application submissions is not yet specified in this pre-announcement.

How much funding would I receive?

Maximum allowable funding varies by award mechanism as anticipated for FY26:

• Clinical Trial Award: up to $4.5 M total costs

• Idea Award: up to $600,000 total costs

• Impact Award: up to $1.5 M (single PI) or $2 M (Partnering PI)
  Note: These are maximums; actual amounts depend on the final FOA.

What could I use the funding for?

Funding supports:

• Clinical trials that advance preclinical research and improve cancer care.

• Innovative basic research that may introduce new paradigms (Idea Award).

• Mature, high-impact hypothesis-driven research with potential near-term impact.

• Applications must address one of the PRCRP topic areas and at least one Military Health Focus Area related to environmental exposures, mission readiness, and gaps in prevention, detection, treatment, or survivorship.

Are there any additional benefits I would receive?

• Alignment with congressional priorities for military health and cancer research.

• Inclusion in the CDMRP funding ecosystem with access to eBRAP pre-application processes and NIH/Grants.gov submission systems.

What is the timeline to apply and when would I receive funding?

• Application deadlines: Not yet specified (will be in final FOAs on Grants.gov).

• Investigators must first submit a pre-proposal via eBRAP before full application.

• Final FOAs will define all submission dates once released.

Where does this funding come from?

Funding is provided by the FY26 Defense Appropriations Act to the Congressionally Directed Medical Research Programs, managed by the Defense Health Agency Research and Development, Medical Research and Development Command.

Who is eligible to apply?

Eligibility varies by mechanism but generally includes independent investigators at all career stages. For Idea Awards, the Early-Career Investigator option is open to those within 7 years of last training and below associate professor rank. Exact institutional eligibility requirements will be in the final FOA.

What companies and projects are likely to win?

Applications that:

• Address at least one FY26 PRCRP Topic Area not covered by other CDMRP cancer programs.

• Clearly relate proposed work to military health, mission readiness, and beneficiary cancer needs.

• Demonstrate scientific merit, innovation/potential impact, and relevance to program goals.
  Projects bridging gaps in prevention, diagnosis, treatment, quality of life, or survivorship in military populations will be competitive.

Are there any restrictions I should know about?

• Final FOAs will specify complete eligibility, topic focus, budget limits, and submission requirements.

• Pre-announcement does not guarantee funding; investigators must wait for formal FOAs on Grants.gov.

How long will it take me to prepare an application?

Preparation time depends on the mechanism:

• Clinical trials need completed preclinical data and IND/IDE submissions before application.

• Idea and Impact Award proposals require scientific groundwork and alignment with topic areas.
  Plan several weeks to months for strategy, pre-proposal, and full application drafts once FOAs are released.

How can BW&CO help?

BW&CO can:

• Interpret final FOAs and clarify topic areas.

• Craft compelling research narratives tied to military health priorities.

• Assist with budgeting, required forms, and eBRAP/Grants.gov submissions.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Melanoma Research Program (MRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Congressionally Directed Medical Research Programs (CDMRP) released a pre-announcement for anticipated FY26 Melanoma Research Program (MRP) funding opportunities. This notice signals that new award mechanisms and funding will be forthcoming, but the application deadlines are not yet specified; they will be published in the formal Funding Opportunity Announcement (FOA) on Grants.gov and eBRAP once available.

How much funding would I receive?

• Idea Award: Maximum total costs up to $560,000 (period up to 2 years).

• Melanoma Academy Scholar Award: Maximum total costs up to $770,000 (period up to 3 years).

• Team Science Award: Maximum total costs up to $2.1 million (period up to 3 years).

• Focused Program Award – Rare Melanomas: Maximum total costs up to $2.8 million (period up to 4 years).

• Survivorship Research Award: Maximum total costs up to $1.015 million (period up to 3 years).

What could I use the funding for?

• All awards must address one or more of the FY26 MRP focus areas:

  • Identify, understand, and mitigate melanoma risk factors and develop biomarkers.

  • Develop detection/diagnosis technologies that improve risk stratification.

  • Define mechanisms of initiation, response/resistance to therapy, progression, recurrence, metastasis.

  • Develop new preclinical models representing disease evolution (cutaneous and rare subtypes).

  • Address unmet needs across cancer research spectrum for rare melanomas.

  • Address psychological/social impacts, quality of life, treatment toxicities, and survivorship issues.

Are there any additional benefits I would receive?

• Melanoma Academy Scholar Award includes mentoring, national networking, and structured career support.

What is the timeline to apply and when would I receive funding?

• The pre-announcement is available now (released February 18, 2026); full FOAs will be released later on Grants.gov.

• Exact pre-application and application deadlines will be specified in those FOAs—not yet provided in the pre-announcement.

• Funding start dates will depend on the FOA timeline and award negotiations—not specified in the pre-announcement.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) under the CDMRP.

Who is eligible to apply?

Eligibility for each award mechanism is defined in the full FOA. From the pre-announcement:

• Idea Award: Investigators at or above the postdoctoral level (or equivalent).

• Melanoma Academy Scholar Award: Investigators within 7 years of first faculty appointment.

• Team Science Award: Independent investigators (Assistant Professor level or equivalent).

• Focused Program Award – Rare Melanomas: Initiating PI at Associate Professor level or equivalent; Partnering PIs at Assistant Professor level or above.

• Survivorship Research Award: Independent investigators (Assistant Professor level or equivalent).

Detailed eligibility criteria (organization types, citizenship, cost share, etc.) will be in the FOA—not specified in the pre-announcement.

What companies and projects are likely to win?

Not specified in the pre-announcement; CDMRP typically funds high-risk, high-gain research that aligns tightly with the listed focus areas and relevance to melanoma biology, detection, survivorship, and unmet clinical needs. Projects that integrate multidisciplinary approaches or include military/VA relevance are typically competitive, but the solicitation does not provide explicit criteria.

Are there any restrictions I should know about?

• The pre-announcement states that submission does not guarantee FOAs or funding.

• All applications must adhere to the final FOA instructions on Grants.gov when released.

• Preliminary data expectations, animal or human subjects requirements, and allowable costs will be defined in the FOA—not yet specified here.

How long will it take me to prepare an application?

• Not specified in the pre-announcement because deadlines are not yet posted. Generally, planning should begin now given the complexity of CDMRP submissions and required pre-applications (e.g., eBRAP).

How can BW&CO help?

BW&CO can:

• Monitor the release of the official FOA and deadlines.

• Translate the FOA into a targeted application strategy.

• Help craft compelling project narrative, budget, and compliance sections.

• Provide review, editing, and submission support to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Ovarian Cancer Research Program (OCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) has released a pre-announcement for the FY26 Ovarian Cancer Research Program (OCRP), outlining anticipated funding opportunities. This pre-announcement allows investigators to begin planning competitive proposals ahead of the formal Funding Opportunity Announcements (FOAs) that will be posted on Grants.gov. Applications will be required to address one or more OCRP priority areas, including novel therapies, early detection, quality of life/survivorship, prevention, and basic ovarian cancer biology. Deadlines for pre-applications and full applications will be provided in the FOAs once published.

How much funding would I receive?

Final funding levels and award amounts will be defined in the FY26 FOAs; estimates from similar past OCRP mechanisms include:

• Clinical Trial Award: Up to $2.8M total costs (max) over up to 4 years

• Investigator-Initiated Research Award: Up to $1.05M (single PI) or $1.4M (Partnering PI) over 4 years

• Ovarian Cancer Academy – Early-Career Investigator Award: Up to $1.125M total costs over 4 years

• Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award: Up to $1.4M total costs over 4 years

• Pilot Award: Up to $350,000 total costs over 2 years

These figures reflect anticipated ceilings based on FY25 mechanisms and are subject to confirmation in the FY26 FOAs.

What could I use the funding for?

Funding supports ovarian cancer research aligned with program priorities:

• Clinical trials and translational research

• Proof-of-concept through early phase studies with potential to impact patient care.

• High-impact investigator-driven research

• Basic through translational research (excluding clinical trials under certain mechanisms).

• Early-career investigator development and mentoring

• Interactive training academies for research and clinical trial skills.

• Innovation and preliminary discovery

• Pilot research to generate data for larger projects.

Are there any additional benefits I would receive?

Beyond funding, OCRP mechanisms like the Academy awards provide:

• Mentoring and networking opportunities for early-career researchers.

• Structured professional development through virtual academy experiences.

• Enhanced visibility within the ovarian cancer research community.

What is the timeline to apply and when would I receive funding?

• Application deadlines: Not yet published in the FY26 pre-announcement; FOAs with specific dates will be posted on Grants.gov once released.

• Pre-application & full application deadlines: Will be included in FOAs.

• Award start dates: After review and programmatic selection; typical NIH/DOD timing suggests awards may begin late in FY26 or early FY27, depending on FOA timelines.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act as part of the DoD’s CDMRP portfolio. OCRP is one of the congressionally directed research programs funded by federal appropriations.

Who is eligible to apply?

Eligibility typically aligns with CDMRP standards:

• Independent investigators (Assistant Professor level or equivalent and above) for most mechanisms.

• Early-career investigators for Academy awards (within defined years of training completion).

• Postdoctoral and clinical fellows for Pilot awards.

Specific eligibility criteria will be detailed in the FY26 FOAs.

What companies and projects are likely to win?

Competitive submissions will:

• Address one or more OCRP areas of emphasis (e.g., early detection, novel therapies, quality of life).

• Demonstrate clinical relevance or strong scientific rationale.

• Present clear pathways to impact ovarian cancer outcomes.

• Align with funding mechanism intent (e.g., ECI development for academy awards).

Projects with rigorous design, transformative potential, and relevance to patient populations are most competitive.

Are there any restrictions I should know about?

Examples based on past OCRP announcements:

• Some mechanisms do not support clinical trials (e.g., Investigator-Initiated Research Award, Pilot Award).

• Applicants may only receive one award per funding cycle from certain mechanisms.

• Pre-application submission is required before full application.

• Investigator eligibility windows apply for early-career awards.

Full restrictions will be in the FY26 FOAs.

How long will it take me to prepare an application?

Preparation time depends on mechanism, but investigators should plan for:

• 8–12 weeks to develop scientific aims, budgets, and letters.

• Additional time if data generation or collaborations are needed.

Starting now will position teams to respond quickly when FOAs are released.

How can BW&CO help?

BW&CO can:

• Interpret OCRP priority areas and align research plans.

• Draft compelling proposals and strong scientific narratives.

• Coordinate submission timelines and compliance packages.

• Support budget and team planning for each mechanism.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Breast Cancer Research Program (BCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Breast Cancer Research Program (BCRP), managed by the Congressionally Directed Medical Research Programs (CDMRP), has released a Pre-Announcement for anticipated Fiscal Year 2026 (FY26) funding opportunities to support innovative, high-impact research aimed at ending breast cancer for Service Members, Veterans, their families, and the general public. This pre-announcement is intended to let investigators plan and develop proposals before the full Funding Opportunity Announcements (FOAs) are posted on Grants.gov. The government does not guarantee awards based on this document alone. FOA release dates, pre-application, and application deadlines will be announced on Grants.gov and eBRAP. Driven investigators should begin conceptualizing competitive approaches immediately.

How much funding would I receive?

The Pre-Announcement outlines anticipated award types with specified maximum total costs for FY26:

Breakthrough Award

• Level 1: up to $750,000 (single PI) or $1.25M (partnering PIs)

• Level 2: up to $1.65M (single PI) or $2.5M (partnering PIs)

• Population Science (Level 2): up to $2.5M (single) or $3.35M (partnering)

• Level 3: up to $5.6M (single) or $7M (partnering)

• Level 4: up to $21M
  (Breakthrough Awards range from early high-risk ideas to transformative approaches.)

Other Anticipated Mechanisms

• Era of Hope Scholar Award: up to $4.9M

• Clinical Research Extension Award: up to $7M (single) / $8.4M (partnering)

• Transformative Breast Cancer Consortium Award: up to $35M

• Transformative Breast Cancer Consortium Development Award: up to $140,000
  (These awards support early-career investigators, ongoing clinical research, and large multi-project consortia.)

What could I use the funding for?

Funded research must address one or more overarching challenges critical to ending breast cancer:

Topic Areas / Research Aims

• Primary prevention of breast cancer

• Determinants of initiation, risk, or susceptibility

• Distinguishing lethal vs. non-lethal tumors

• Solutions to overdiagnosis/overtreatment

• Pathways driving tumor growth and metastasis

• Mechanisms of dormancy and lethal recurrence

• More effective, less toxic treatments

• Reducing mortality from metastatic disease

Mechanism-Specific Uses

• Breakthrough Awards: high-risk/high-reward or translation-focused research

• Era of Hope Scholar Award: early-career leadership and innovation

• Clinical Research Extension: extending clinical data collection and analysis

• Consortium Awards: integrated multi-project collaborations toward transformative goals

(Mechanism scopes will be confirmed in the FOAs.)

Are there any additional benefits I would receive?

Participating teams may benefit from:

• Collaborative frameworks with consumer advocates required on some mechanisms

• Access to eBRAP support and templates for submission guidance

What is the timeline to apply and when would I receive funding?

• Pre-Announcement Released: February 2026 (no exact FOA deadlines yet)

• FOAs and deadlines: Will be posted on Grants.gov and eBRAP once finalized.

• Plan: Prepare project concepts now; watch Grants.gov and eBRAP for pre-application and application due dates, which may be weeks to months after FOA publication. Award start dates typically follow after review and appropriation obligations.

Where does this funding come from?

This funding is provided by the FY26 Defense Appropriations Act under the Department of Defense’s Congressionally Directed Medical Research Programs, specifically appropriated for breast cancer research.

Who is eligible to apply?

Eligibility varies by mechanism but generally includes:

• Investigators at all academic levels or equivalent (Breakthrough, Clinical Extension)

• Independent investigators (higher level awards)

• Teams including consumer advocates for specified awards

• Exact eligibility will be detailed in each FOA.

(Final eligibility criteria are determined in the FOAs.)

What companies and projects are likely to win?

Competitive proposals typically:

• Address key overarching challenges defined by BCRP

• Demonstrate innovation, clinical relevance, and impact

• Include translational pathways or transformative potential

• Meet mechanism-specific expectations (e.g., data access plans, interdisciplinary teams)

Are there any restrictions I should know about?

• This pre-announcement is not a FOA and does not guarantee funding.

• Final applications must conform to Grants.gov FOAs once released.

• Mechanism specific limits on clinical trials and preliminary data requirements will be in each FOA.

How long will it take me to prepare an application?

Preparation time varies by project complexity, but given the breadth of mechanisms and expected competitive standards, begin planning now while awaiting FOAs:

• Concept refinement: ~2–4 weeks

• Team assembly & consumer advocate engagement: ~2–6 weeks

• Budget & prelim data planning: ~4–8+ weeks depending on scope

How can BW&CO help?

BW&CO can assist with:

• Translating BCRP FOA language into tailored project responses

• Drafting narrative, budget justification, and impact sections

• Aligning your concept with mechanism-specific review criteria

• Incorporating consumer review perspectives where required

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.